Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy.
about
Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistanceAbsence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected miceOral antiviral drugs in experimental herpes simplex keratitisLong term oral acyclovir in disseminated mucocutaneous herpes simplex: a case reportEnzymology and pathogenicity in mice of a herpes simplex virus type 1 mutant resistant to 2'-fluoro-2'-deoxy-1-beta-D-arabinofuranosyl-5-iodocytosineThymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models.Chemotherapy for herpes simplex virus infectionsHigh-frequency phenotypic reversion and pathogenicity of an acyclovir-resistant herpes simplex virus mutant.Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapyOrofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs.Comparative methods for detection of thymidine kinase-deficient herpes simplex virus type 1 strainsPathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene.Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs.Perspectives in antiviral chemotherapy.Persistent herpes simplex virus infection and mechanisms of virus drug resistance.Penciclovir susceptibilities of herpes simplex virus isolates from patients using penciclovir cream for treatment of recurrent herpes labialis.In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study.HSV1 strain sensitivity in experimental rabbit keratitis: evolution under repeated topical IDU administrations.Effect of L-lysine monohydrochloride on cutaneous herpes simplex virus in the guinea pig.
P2860
Q24634966-EF1FA15A-1771-493E-92F5-1242EF01FABEQ24797196-CB334EF3-19DF-4890-BF7F-A27D84428A01Q28366300-F218ACDA-3771-4361-A994-B9DB65182182Q33660836-E2E20B4C-4CA9-47D5-8E4D-0AB6922B320BQ33739362-3B5A7401-971A-474F-983D-44E567405CDDQ33864322-55BE873B-F94E-42C5-A8B1-F358258C44F2Q33980794-05259C30-1E56-4066-8E7A-408A780117DAQ34193041-49668B52-E649-4856-9455-77A346C92CBCQ34467256-60E43D3B-0F8A-4027-B037-C1783581AA3FQ34579981-9152C350-03B1-442F-B70F-1FE74F4B8D4DQ35244752-6390CA4F-3CC4-4B29-AC19-FCB145238BB7Q35540860-5C13574F-7669-478A-B807-D2A2AED3C4DEQ35569432-2BE91C14-D2FA-4002-880B-C1A3333D0350Q35575128-2C42BEBD-940C-43AC-963B-D315709FD435Q36883978-D6EE83FC-B41D-4C85-B9A5-3D1B1E3258A0Q36903164-520DCC5E-6D16-417F-9FC7-F1ED9CA5F9E2Q37959377-443F1588-0EB9-4523-A0B8-812A8CF7A2BDQ38287183-75F04F3D-5974-4045-A44E-76A108CABF8CQ39652814-9B5CDB5C-7952-460A-90CD-0CEB538086B9Q40088021-B163A5CF-0B88-4207-86F2-A83B76E3FAEAQ44503087-69DDFA90-A998-4C96-843A-A98139B86640Q45119443-23CBDDFE-5841-431D-AA7A-4943433A0F13Q45845973-9DD7A009-9A42-4E61-91D0-95E8F4BA0A7B
P2860
Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
Development of clinical resist ...... d mice receiving oral therapy.
@en
Development of clinical resist ...... d mice receiving oral therapy.
@nl
type
label
Development of clinical resist ...... d mice receiving oral therapy.
@en
Development of clinical resist ...... d mice receiving oral therapy.
@nl
prefLabel
Development of clinical resist ...... d mice receiving oral therapy.
@en
Development of clinical resist ...... d mice receiving oral therapy.
@nl
P2860
P356
P1476
Development of clinical resist ...... d mice receiving oral therapy.
@en
P2093
P2860
P304
P356
10.1128/AAC.21.5.744
P407
P577
1982-05-01T00:00:00Z